ICIG buys Tessenderlo Group’s pharma ingredients activities

Published: 23-Jan-2013
Ingredients Finance

Divestment in line with strengthened focus on speciality products and services


Tessenderlo Group has completed the sale of its pharmaceutical ingredients activities in Calaire (France) and Farchemia (Italy) to International Chemical Investors Group (ICIG), a private industrial holding company.

The Tessenderlo Group announced in October 2012 its intention to divest the pharmaceutical ingredients activities at Calaire and Farchemia, which have some 360 employees. After clearance by the merger control authorities, the sale was completed on 5 December 2012.

This divestment is in line with Tessenderlo Group’s strengthened focus on speciality products and services in the areas of food, agriculture and water management.

ICIG is a privately-owned industrial holding company focusing on mid-sized chemicals and pharmaceutical businesses. Since its inception in 2004, it has acquired 19 independent chemicals and pharmaceutical businesses with total sales of approximately €780m. It has not announced its plans for the new purchase.

See more

You may also like

Ingredients

FrieslandCampina Ingredients debuts consumer-driven concepts at Vitafoods Europe

Read more
The company will exhibit its omega-3 ingredient, as well as its active gut health solution

Trending Articles

  1. Adult vaccination programmes deliver significant socio-economic benefits, study finds The study shows that adult immunisation programmes return 19x their initial investment, which could ease the pressure on health systems
  2. Prima BioMed announces new product candidate IMP761: a LAG-3 agonist antibody Prima BioMed announces that it has developed a new early stage product candidate, a humanised IgG4 monoclonal antibody to be known as IMP761
  3. Causes and solutions for dark spots in tablet manufacturing Natoli Engineering examines the causes and solutions for dark spots that can halt production
  4. CordenPharma & GENEPEP collaborate to leverage peptide drug substance discovery The partnership has facilitated the expedition of the development, discovery and manufacturing of peptides for early clinical phase
  5. Highly potent APIs: Hazards in classification and handling This variability and subjective nature of classification means that the OEL is best considered as a tool for site risk management teams

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

You may also like

Ingredients

FrieslandCampina Ingredients debuts consumer-driven concepts at Vitafoods Europe

The company will exhibit its omega-3 ingredient, as well as its active gut health solution
Drug Delivery

Adult vaccination programmes deliver significant socio-economic benefits, study finds

The study shows that adult immunisation programmes return 19x their initial investment, which could ease the pressure on health systems
Manufacturing

CordenPharma & GENEPEP collaborate to leverage peptide drug substance discovery

The partnership has facilitated the expedition of the development, discovery and manufacturing of peptides for early clinical phase
Ingredients

Therapeutic: acoramidis for transthyretin amyloid cardiomyopathy

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a rare progressive disease that results from genetic mutations or ageing; misfolded TTR protein accumulates as amyloid fibrils in the myocardium
Ingredients

Therapeutic: lutikizumab for hidradenitis suppurativa

Hidradenitis suppurativa (HS) — also known as acne inversa — is a chronic, recurrent and progressive inflammatory disease that leads to irreversible skin damage and disability
Ingredients

Olon: celebrating 10 years of daptomycin and doubled production capacity

Olon's Daptomycin celebrates its 10th anniversary, and in the very year that marks the first decade of production of this first in a new class of antibiotics that represented a breakthrough in the treatment of skin infections, the leading API supplier group announces the doubling of its production to meet and exceed global demand for the active ingredient
Regulatory

Policy vacuum risks UK becoming a medicines supply backwater

The UK becoming a "backwater" supply marker could jeopardise £18bn of NHS savings from newly off-patented drugs during the next five years
Subscribe now